Long-term follow-up MR imaging in children with transverse myelitis.

Autor: El Naggar I; Department of Pediatric Neurology, Children´s Hospital Datteln, University Witten/Herdecke, Dr. Friedrich-Steiner Str. 5, Datteln D-45711, Germany., Cleaveland R; Department of Pediatric Radiology, Children´s Hospital Datteln, University Witten Herdecke, Datteln, Germany., Panzer A; Department of Pediatric Radiology, Children´s Hospital Datteln, University Witten Herdecke, Datteln, Germany., Molenaar S; Department of Neurology, ErasmusMC Rotterdam, Rotterdam, the Netherlands., Giorgi L; Department of Pediatric Neurology, Assistance Publique-Hôpitaux de Paris, University Hospital Paris Saclay, French National Reference Center for Rare Inflammatory/auto-immune brain and spinal diseases (MIRCEM), Paris-Saclay University, Paris, France., Wendel EM; Division of Pediatric Neurology, Department of Pediatrics, Olgahospital, Stuttgart, Germany., Bertolini A; Department of Pediatric Neurology, Children´s Hospital Datteln, University Witten/Herdecke, Dr. Friedrich-Steiner Str. 5, Datteln D-45711, Germany., Karenfort M; Clinic of general Pediatrics, Neonatology and Pediatric Cardiology, Düsseldorf University Hospital, Heinrich-Heine-University, Düsseldorf, Germany., Thiels C; Division of Pediatric Neurology, Clinic of Pediatrics, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany., Libá Z; Department of Pediatric Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic., Baumann M; Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria., Leiz S; Pediatric Neurology, Department of Pediatrics and Adolescent Medicine, Kliniken Dritter Orden, Munich, Germany., Della Marina A; Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- und Behavioral Sciences, University Duisburg-Essen, Essen, Germany., Hengstler JG; Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University Dortmund, Dortmund, Germany., Deiva K; Department of Pediatric Neurology, Assistance Publique-Hôpitaux de Paris, University Hospital Paris Saclay, French National Reference Center for Rare Inflammatory/auto-immune brain and spinal diseases (MIRCEM), Paris-Saclay University, Paris, France; MR 1184 'Immunology of viral infections and autoimmune diseases', Paris-Saclay University, Senior Member Institute Universitaire de France, France and ERN-RITA, France., Neuteboom R; Department of Neurology, ErasmusMC Rotterdam, Rotterdam, the Netherlands., Reindl M; Medical University of Innsbruck, Innsbruck, Austria., Rostásy K; Department of Pediatric Neurology, Children´s Hospital Datteln, University Witten/Herdecke, Dr. Friedrich-Steiner Str. 5, Datteln D-45711, Germany. Electronic address: kevin.rostasy@uni-wh.de.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Dec; Vol. 92, pp. 105926. Date of Electronic Publication: 2024 Oct 11.
DOI: 10.1016/j.msard.2024.105926
Abstrakt: Background: We recently described magnetic resonance imaging (MRI) features of children with transverse myelitis (TM) at first event with important and unique differences depending on the underlying disease entity.
Objective: To study the resolution of lesions over time in children with TM due to MOG-antibody associated disorders (MOGAD), multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) or double seronegative TM.
Patients and Methods: In this prospective study, 78 children from 29 different medical centres with TM as part of MOGAD (n = 34), MS (n = 20), NMOSD (n = 5) and in double seronegative children (n = 19) were included. A grading system consisting of 4 grades (grade 0 = complete resolution; grade 3 = no resolution at all) was used to compare the degree of lesion resolution over time in the different disease entities. Time to lesion resolution was evaluated by Kaplan-Meier statistics and log-rank test.
Results: Significant differences of the interval between first MRI until resolution of lesions were observed between the four disease entities. The most rapid and complete resolution was seen in MOGAD, followed by double seronegative, MS and NMOSD. Median periods until total resolution (grade 0) were 191 days (MOGAD), 750 days (double seronegative), 1117 days (MS), while none of the patients with NMOSD reached a complete resolution during the observation period. The better prognosis of MOGAD compared to MS was independent of sex, age, oligoclonal bands and cell count in the multivariate Cox analysis (P < 0.001).
Conclusion: Children with TM and antibodies to MOG show a faster resolution of radiological lesions compared to children with MS and NMOSD.
Competing Interests: Declaration of competing interest Ines El Naggar: received travel grants from UCB. Eva-Maria Wendel: received travel grants from UCB. Annikki Bertolini: received travel grants from UCB. Markus Reindl: was supported by research grants from the Austrian Science Fund (FWF projects P32699 and IPN170), the Austrian Research Promotion Agency and Roche. Deiva Kumaran: received honoraria for invited talks for Biogen, Alexion, Sanofi and serves as consultant for Novartis and Horizon. Rinze Neuteboom: participated in pharmacological studies in demyelinating disorders with Roche, Horizon, Novartis and Sanofi-Genzym. Funding from Dutcht MS research foundation, Dreams Foundation, Postcode Loterij, Vrienden Sophia Foundation. Kevin Rostásy: received honoraria for invited talks from Horizon, UCB and serves as a consultant in the OperettaII study. Robert Cleaveland, Andreas Panzer, Sandy Molenaar, Laetitia Giorgi, Michael Karenfort, Charlotte Thiels, Zuzana Libá, Matthias Baumann, Steffen Leiz, Adela Della Marina, Jan G. Hengstler, members of the BIOMARKER study group (Steffen Berweck, Astrid Blaschek, Matthias Eckenweiler, Astrid Eisenkölbl, Tobias Geis, Annette Hackenberg, Verena Kraus, Heinz Lauffner, Daniela Pohl, Martin Pritsch, Michela Salandin, Torsten Sandrieser, Mareike Schimmel, Christoph von Kleist-Retzow, Gert Wiegand): no conflict of interest
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: